Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (EXEL), Edwards Lifesciences (EW) and Zimmer Biomet Holdings (ZBH)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exelixis (EXEL – Research Report), Edwards Lifesciences (EW – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Exelixis (EXEL)
Wells Fargo analyst Derek Archila maintained a Hold rating on Exelixis today and set a price target of $35.00. The company’s shares closed last Tuesday at $42.98.
According to TipRanks.com, Archila is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $47.18 average price target, a 7.3% upside from current levels. In a report issued on January 29, RBC Capital also maintained a Hold rating on the stock with a $45.00 price target.
See the top stocks recommended by analysts >>
Edwards Lifesciences (EW)
Wells Fargo analyst Larry Biegelsen reiterated a Buy rating on Edwards Lifesciences today and set a price target of $100.00. The company’s shares closed last Tuesday at $77.05.
According to TipRanks.com, Biegelsen is a 3-star analyst with an average return of
Edwards Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $97.50, a 26.8% upside from current levels. In a report issued on January 30, Piper Sandler also maintained a Buy rating on the stock with a $98.00 price target.
Zimmer Biomet Holdings (ZBH)
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings, with a price target of $112.00. The company’s shares closed last Tuesday at $91.40.
According to TipRanks.com, Zimmerman is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Zimmer Biomet Holdings with a $101.27 average price target, implying a 7.6% upside from current levels. In a report issued on January 30, TD Cowen also upgraded the stock to Buy with a $109.00 price target.
